Abstract
490
Objectives Only one commercial kit for the preparation of 99mTc macro aggregated albumin (MAA) is available in the US. The current method of preparing a particle dependent dosage uses the reconstituted MAA solution to be labeled with 99mTc. Information on the stability of this solution is lacking. Our objective was to evaluate the stability of MAA solution using radiochemical purity (RCP) and particle size of 99mTc MAA.
Methods Over 12 months, commercially available MAA reaction vials were reconstituted with normal saline and the solution repackaged into vials containing 500,000 particles per 1 mL in a commercial nuclear pharmacy setting in accordance with USP 797. Vials were stored at 2°C to 8°C for 3 to 14 days before labeling with 99mTc. Contents were drawn into 3 mL BD syringes and stored at 20°C to 25°C for up to 24 hours. RCP and particle size were evaluated initially and at 24 hours using a method previously described. Correlations between 99mTc mole fractions and storage times to RCP were calculated.
Results 36 samples were analyzed. Four different lots of MAA were used; n=3, 15, 3, and 12 respectively. The solution was stored for an average of 8 days (SD ± 4 days). The average activity was 34.2 mCi (SD ± 3.8 mCi). The average 99mTc mole fraction was 0.41 (range 0.17 to 0.59). Storage temperature was 5°C ± 2°C. The mean RCP of the 99mTc-MAA was 97.7% (range 85.5% to 100%) initially and 96.2% (range 38% to 99.9%) at 24 hours. The size of the particles ranged from 10 to 150 micrometers with 90% being 10 to 50 micrometers. There was a correlation between storage time and RCP (r = -0.25) and 99mTc mole fraction (r = 0.2).
Conclusions Taking into consideration elution quality and storage conditions, repackaging MAA does not appear to affect the stability of the MAA solution to form stable 99mTc-MAA. While 34 of our samples met USP RCP parameters of 蠅 90%, two did not. In addition there may be procedures that require higher RCP limits than USP.